BRD0705 is a potent, paralog selective and orally active GSK3α inhibitor. BRD0705 can be used for acute myeloid leukemia.

Product information

CAS Number: 2056261-41-5

Molecular Weight: 321.42

Formula: C20H23N3O

Chemical Name: (S)-4-ethyl-7, 7-dimethyl-4-phenyl-1, 2, 4, 6, 7, 8-hexahydro-5H-pyrazolo[3, 4-b]quinolin-5-one

Smiles: CC1(C)CC2N=C3NNC=C3[C@@](CC)(C=2C(=O)C1)C1C=CC=CC=1

InChiKey: NCKLQXXBRWCYMA-FQEVSTJZSA-N

InChi: InChI=1S/C20H23N3O/c1-4-20(13-8-6-5-7-9-13)14-12-21-23-18(14)22-15-10-19(2,3)11-16(24)17(15)20/h5-9,12H,4,10-11H2,1-3H3,(H2,21,22,23)/t20-/m0/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO: 300 mg/mL (933.36 mM)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

References:

1. Wagner FF, et al. Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Sci Transl Med. 2018 Mar 7;10(431). pii: eaam8460.

Products are for research use only. Not for human use.